Loading clinical trials...
Loading clinical trials...
A Randomized, Multicenter, Open-label, Phase 2 Study, With a Safety Run-in Part to Evaluate Safety, Pharmacodynamics and Efficacy of Azacitidine Compared to No Anticancer Treatment in Children and Young Adults With Acute Myeloid Leukemia in Molecular Relapse After First Complete Remission
Conditions
Interventions
Azacitidine
Control Arm
Locations
8
Denmark
Rigshospitalet
Copenhagen, Denmark
Charite Berlin
Berlin, Germany
Universitatsklinikum Essen
Essen, Germany
Klinikum der Johann Wolfgang Goethe-Universität Frankfurt/Main
Frankfurt am Main, Germany
Universitatsklinik
Freiburg im Breisgau, Germany
Medical School of Hannover
Hanover, Germany
Start Date
August 12, 2015
Primary Completion Date
October 10, 2018
Completion Date
October 8, 2019
Last Updated
December 20, 2019
NCT06852222
NCT06580106
NCT06501196
NCT06384261
NCT06382168
NCT06326268
Lead Sponsor
Celgene
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions